Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion
Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as successor. The company anticipates a strong FY27 launch calendar, particularly in the second half, with a focus on ...
Kiran Mazumdar-Shaw, Biocon's Executive Chairperson, has mapped out a five-year leadership transition, a back-half heavy FY27 launch calendar, and a diabesity franchise she believes will be a defining asset, while warning no company can absorb a prolonged West Asia conflict.
Mazumdar-Shaw used Biocon's FY26 earnings call to address three things that markets have been watching closely, the company's succession plan, the trajectory of its biosimilar pipeline, and the pace of its debt reduction, and on each count, she came with specifics.
Succession: Claire Mazumdar gets five years
The most closely watched disclosure was Mazumdar-Shaw's confirmation that her niece, Claire Mazumdar, is being groomed as her successor at the helm of Biocon. Talking to ET Now, she was explicit that this is not an immediate handover but a structured five-year transition, during which Claire will work alongside her to absorb the business — a business she said Claire already understands deeply, having grown up in proximity to it.
Claire's credentials, Mazumdar-Shaw argued, are not merely familial. As founder of Bicara Therapeutics — which began as a Biocon subsidiary, listed independently, and earned a breakthrough designation for one of its assets — Claire has demonstrated she can raise capital, run a public company, and build a pipeline. Biocon today holds only about 10% of Bicara, and Mazumdar-Shaw was clear there are no plans to reabsorb it. Claire will transition out of Bicara over the five-year window before stepping into the Biocon chairperson role.
She has earned her stripes. I give her about five years in which I can hand over charge — she will work alongside me and understand what this business is about.
Mazumdar-Shaw signalled that investors should not expect an even spread of results through FY27. The first quarter will be relatively muted on new product contribution, but the second half is expected to see a strong ramp-up across multiple launches. Denosumab has already made its US market entry and will build share progressively. Aflibercept enters the US market in H2 following a patent settlement. And KIRSTY, Biocon's insulin aspart product, will see an aggressive commercial push this fiscal year.
The insulin franchise — which has already crossed $300 million in revenue, anchored by biosimilar Glargine (SEMGLEE) — is set to expand further as aspart adds a second major product to the portfolio. Liraglutide is also being prioritised for market expansion in Europe and the US, where Mazumdar-Shaw sees meaningful opportunity.
ADVERTISEMENT
On semaglutide, she tempered near-term expectations. While competition across markets is intensifying — with Canadian entry already attracting several Indian players — Biocon's differentiated position, she argues, lies in its full vertical integration and deep device expertise from the insulin business. The real scale-up, she says, begins in FY28, at which point she expects semaglutide to become a large contributor across multiple geographies alongside insulins, forming what she called a unique "diabesity franchise."
Two QIPs totalling nearly $1 billion were deployed through FY26 to retire structured debt and reduce the acquisition-related debt overhang. The full interest benefit — roughly ₹75 crore per quarter — will only be fully reflected in FY27 numbers. Mazumdar-Shaw said any further cash generated from operations will be prioritised toward additional debt reduction, though she noted the company is already at a level it considers comfortable on debt-to-EBITDA metrics.
On the R&D front, the company is targeting a 7–8% spend band, which she says is sufficient to sustain a robust biosimilar pipeline, particularly as regulatory pathways for biosimilars have been shortened — a structural tailwind Biocon is now actively harvesting.
